Mebendasole is better absorbed in the gastrointestinal tract if administered together with essential to patients with hydatid disease. Thirty-four patients with alveolar and hydatid echinococcosis were administered mebendasol in a daily dose of 50 mg/kg in 4 doses and essentiale in a daily dose of 600-1000 mg in 4 doses. A total of 86 therapeutic courses, 30 days each, were carried out. The treatment was sufficiently well tolerated. Mebendasole levels in the course of therapy surpassed the minimal effective ones in 2/3 of the patients, that is, they were significantly higher than in administration of mebendasole alone.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of a proprietary extract in skin health - a randomized, placebo-controlled clinical study in healthy volunteers.
Am J Transl Res
December 2024
Trial Guna Private Limited 476, JP Nagar, Bangalore 560083, India.
Objectives: The concept of beauty from within is a growing trend in the market and people now look for oral supplements that can enhance the well-being of skin from within. Within this principle, a proprietary pomegranate extract (Grantria), standardized to ellagic acid, punicic acid and punicalagin, was developed using ADOP (Advanced Oil-Powder) technology and was clinically evaluated for its efficacy and safety in healthy adults.
Methods: This evaluation was carried out as a randomized, placebo-controlled clinical study for 60 days at a daily dose of 300 mg.
Efficacy of Bilastine, Dextromethorphan, and Phenylephrine Syrup in Patients With Dry Cough: A Phase 3 Randomised Trial.
Cureus
December 2024
Research and Development, Glenmark Pharmaceuticals Limited, Mumbai, IND.
Background Cough in common cold is often associated with rhinorrhoea and nasal congestion, requiring treatment with a cough suppressant, decongestant, and antihistamine. Bilastine is a non-sedating antihistamine, a preferred option over sedating antihistamines. A combination of bilastine, dextromethorphan, and phenylephrine is expected to provide non-sedating treatment for cough associated with a common cold or allergy.
View Article and Find Full Text PDFCryoneurolysis and Quadriplegia: A Case Report on Pain and Severe Spasticity Management.
Arch Rehabil Res Clin Transl
December 2024
Vancouver Island Health Authority, Victoria, BC, Canada.
Spasticity, a common symptom after spinal cord injury, often leads to pain, muscle contracture, and compromised daily activities. Cryoneurolysis, a minimally invasive, drug-free procedure for the treatment of pain, is now gaining recognition for treating spasticity. It involves using an ultrasound-guided probe to freeze and destroy overactive target nerves.
View Article and Find Full Text PDFEffects of dietary oregano essential oil supplementation on carcass traits, muscle fiber structure, oxidative stability, meat quality, and regulatory mechanisms in Holstein steers.
J Sci Food Agric
January 2025
College of Animal Science and Technology, Gansu Agricultural University, Lanzhou, China.
Background: Dietary supplementation for beef cattle, using natural plant extracts, such as oregano essential oil (OEO), has proven effective in enhancing growth performance, beef production quantity and quality, and ensuring food safety. However, the precise mechanisms underlying these effects remain unclear. This study investigated the impact of OEO on carcass traits, muscle fiber structure, meat quality, oxidative status, flavor compounds, and gene regulatory mechanisms in the longissimus thoracis (LT) muscles of beef cattle.
View Article and Find Full Text PDFA physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment.
J Pharmacokinet Pharmacodyn
January 2025
Department of Clinical Pharmacy and Pharmacy Administration, West China school of Pharmacy, Sichuan University, Chengdu, 610064, China.
Alogliptin is a highly selective inhibitor of dipeptidyl peptidase-4 and primarily excreted as unchanged drug in the urine, and differences in clinical outcomes in renal impairment patients increase the risk of serious adverse reactions. In this study, we developed a comprehensive physiologically-based quantitative systematic pharmacology model of the alogliptin-glucose control system to predict plasma exposure and use glucose as a clinical endpoint to prospectively understand its therapeutic outcomes with varying renal function. Our model incorporates a PBPK model for alogliptin, DPP-4 activity described by receptor occupancy theory, and the crosstalk and feedback loops for GLP-1-GIP-glucagon, insulin, and glucose.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!